Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358852 | 0.91 | HTT (0.70) | MAPTKCNA5ALDH1A1HTTHSD17B10 | |
| SCHEMBL19358850 | 0.88 | CA1 (0.72) | MAPTALDH1A1OPRK1L3MBTL1HTT | |
| SCHEMBL19358877 | 0.86 | ALDH1A1 (0.76) | MAPTALDH1A1OPRK1MEN1KMT2A | |
| SCHEMBL19358883 | 0.84 | MAPT (0.63) | MAPTALDH1A1OPRK1L3MBTL1HTT | |
| SCHEMBL19358915 | 0.84 | CA1 (0.67) | MAPTALDH1A1OPRK1HTTMEN1 | |
| SCHEMBL19358924 | 0.84 | MAPT (0.74) | MAPTALDH1A1OPRK1L3MBTL1HTT | |
| SCHEMBL16430155 | 0.83 | KMT2A (0.77) | MAPTOPRK1MEN1KMT2ARAB9A | |
| SCHEMBL5334260 | 0.83 | MMP13 (0.85) | ALDH1A1MEN1KMT2AMMP13LMNA | |
| SCHEMBL19358853 | 0.82 | TP53 (0.81) | MAPTALDH1A1OPRK1MEN1KMT2A | |
| SCHEMBL10047336 | 0.81 | CYP19A1 (0.76) | MAPTKCNA5ALDH1A1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429588-B1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | UNIV EMORY (US) | 2024-09-18 | — | — | EP | disclosed |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | EMORY UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | EMORY UNIVERSITY (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3429588-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | Emory University (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160832-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | EMORY UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | CXCR4, CXCL12, CXCR2 | MAPT 4641/4885KCNA5 3643/4885ALDH1A1 352/4885 |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | CXCR4, CXCL12, CXCR2 | MAPT 4641/4885KCNA5 3643/4885ALDH1A1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.